Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Bioprinting, Biofabrication, Organoids & Organs-on-Chips Asia 2022

3D-Bioprinting, Biofabrication, Organoids & Organs-on-Chips Asia 2022 Agenda

Co-Located Conference Agendas

Flow Chemistry Asia 2022 | 3D-Bioprinting, Biofabrication, Organoids & Organs-on-Chips Asia 2022 | Lab-on-a-Chip and Microfluidics Asia 2022 | 

Print Agenda

Thursday, 6 October 2022

Please Refer to the Lab-on-a-Chip and Microfluidics Asia 2022 Track Agenda for Details of Programming on Thursday, 06 October 2022

Friday, 7 October 2022


Morning Coffee, Tea and Networking in the Exhibit Hall


Danilo TagleKeynote Presentation

The NIH Microphysiological Systems Program: Tissue Chips for Tools for Drug Development and Precision Medicine
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. A number of these failures can be attributed to poor predictability of human response from animal and 2D in vitro models currently being used in drug development. To address this challenges in drug development, the NIH Tissue Chips or Microphysiological Systems program is developing alternative innovative approaches for more predictive readouts of toxicity or efficacy of candidate drugs. Tissue chips are bioengineered 3D microfluidic platforms utilizing chip technology and human-derived cells and tissues that are intended to mimic tissue cytoarchitecture and functional units of human organs and systems. In addition toxicity studies in drug development, these microfabricated devices are also being used to model various human diseases for assessment of efficacy of candidate therapeutics. A more recent program is the development of “clinical trials on chips” to inform clinical trial design and implementation, and for studies in precision medicine. Presentation will provide a program update and future directions towards widespread use of tissue chip technologies in partnerships with various stakeholders.


Electrochemical Analysis of Vasculature-on-a-Chip and Vascularized-3D-Model-on-a-Chip
Yuji Nashimoto, Associate Professor, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Japan

During this decade, bioengineering technologies to make a perfusable vascular model and integrate it with a three-dimensional culture model shows great advancement. However, analytical systems to evaluate vascular function and its effects are still limited. In this presentation, the electrochemical platform to evaluate vascular permeability, topography, and the transvascular flow effects on 3D tissue will be demonstrated. The analytical platform is promising for read-outs of the functionality of the vascular model and vascularized 3D model in a microphysiological system.


Microphysiological Systems (MPS) by Designing the Interface of Epithelial and Endothelial Cells
Ryuji Yokokawa, Professor, Department of Micro Engineering, Kyoto University, Japan

Microfluidic devices have become popular in many life science fields, including stem cell research. As a microfabrication scientist, I have been proposing new assay systems as microphysiological systems (MPS). The assay systems that mimic the functions of human biological organs can be constructed on a chip to measure physiological functions that are difficult to measure on a culture dish. We have employed two approaches to create the interface between organ cells and vascular networks in MPS: a two-dimensional method in which organ cells and vascular endothelial cells are co-cultured on the top and bottom surfaces of a porous membrane coated with an extracellular matrix, such as Transwell (2D-MPS), and a three-dimensional method in which the spontaneous patterning ability of vascular endothelial cells is utilized (3D-MPS). A 2D-MPS, renal proximal tubule model, evaluates albumin and glucose reabsorption and nephrotoxicity, while the glomerular filtration barrier model evaluates inulin and albumin filtration mechanisms. I will also present recent results on the development of a co-culture system of organoids and vascular network as a 3D-MPS. Kidney and brain organoids were cultured on a vascular network to demonstrate their maturation and vascularization. The on-chip vascular network is expected to expand from basic researches including vascular biology to evaluate the correlation between shear stress and vascular morphogenesis.


Mid-Morning Coffee, Tea and Networking in the Exhibit Hall


Shoji TakeuchiKeynote Presentation

From Lab to Fork: 3D Tissue Engineering For Meat Production
Shoji Takeuchi, Professor, Center For International Research on Integrative Biomedical Systems (CIBiS), Institute of Industrial Science, The University of Tokyo, Japan

Research on "cultured meat," as typified by cultured hamburgers and chicken nuggets, has been studied world wide. These were made from randomly arranged muscle cells, so-called "minced meat." In contrast, our research group has been working on the in vitro fabrication of 3D structures of muscle tissue with the goal of realizing steak meat with its original texture. Bovine muscle tissue in the shape of a dice steak (1.0 cm x 0.8 cm x 0.7 cm) was prepared by forming a gel containing myoblasts grown from bovine muscle satellite cells into a sheet shape, stacking the sheet with both ends fixed to anchors, and culturing it. Myofibers in the tissue showed sarcomere-like structures stained with anti-a-actinin antibodies, suggesting that the myofibers were not just an aggregate of myoblasts, but that myoblasts fused with each other and underwent differentiation. In addition to these results, the latest developments will be presented in this talk.


Light-Induced 3D Bioprinting Technologies
Daniel Nieto, Head of Biofabrication and Tissue Engineering unit. , University of Santiago de Compostela, Spain

An overview of some photo curing-based bioprinting technologies, including Digital Light Projection, Volumetric bioprinting and a light-based biopen for biomedical applications is presented.


Networking Lunch in the Exhibit Hall -- Visit Exhibitors and View Posters -- Japanese Bento Box Lunch


Biomimetic Vascular Constructs Using Three-Dimensionally (3D) Printed Porous Molds
Michinao Hashimoto, Associate Professor, Singapore University of Technology and Design, Singapore

We present a method to fabricate anatomically relevant vascular models using 3D-printed molds. Advanced biofabrication methods—sacrificial molding, direct ink writing, coaxial bioprinting, and embedded bioprinting—have enabled the fabrication of vascular models with intricate 3D architecture. Despite their advances, however, achieving full anatomical mimicry of native vasculature (such as freestanding, branching, multilayered, perfusable, and mechanically stretchable) remains to be challenging. In this work, we demonstrated an alternative biofabrication method for freestanding cell-laden vascular constructs with complex 3D architecture. The fabrication is achieved by employing a two-part mold consisting of porous hydrogels. The diffusion of calcium chloride (Ca2+) ions from the mold prompted dynamic crosslinking of the alginate-containing hydrogels in the radially inward direction to form a tubular construct. The same approach was extended to employing molds with complex shapes to achieve intricate 3D vascular architecture. The fabricated vascular models may be laden with smooth muscle cells (SMCs) and endothelial cells (ECs) in the multilayered arrangement. Lastly, vascular constructs with anatomically accurate geometries (e.g., constructions, bifurcation) and mechanical stress (e.g., cyclical motion) were readily fabricated. These vasculature models with increased biomimicry should benefit future research in mechanistic understanding of cardiovascular diseases and their therapeutic intervention.


CELLINK3D Bioprinting Technologies For Organ-on-a-Chip Fabrication
Haruka Yoshie, Application Specialist, CELLINK

Organ-on-chips are microfluidic-based devices which allow researchers to study various biomedical aspects and processes including different pathological models and drug development and screening. Great efforts have been made for the development of organ-on-chips in recent years to more closely mimic cellular microenvironment, and to better understand more complex cell-cell interactions in vitro. To fabricate organ-on-a-chip devices, 3D fabrication methods are required. 3D bioprinting technology is rising as an innovative tool to fabricate organ-on-chips as it enables manufacturing of cell-laden microfluidic systems utilizing multiple materials and cell types in a controlled manner. There are different 3D bioprinting approaches to fabricate channel like structures in microfluidics/organ-on-chips, depending on the desired model. Recent advancement in extrusion-based bioprinting technologies such as coaxial printing and embedded printing (e.g. FRESH printing technique) allows creation of cell-laden in-vitro microfluidic devices. Light-based bioprinting is another approach to the fabrication of organ-on-chip devices. In this presentation, CELLINK 3D bioprinting technologies will be introduced. Our technologies are applied to various organ-on-a-chip models including disease models like tumor-on-a-chip studies. The studies demonstrate that the 3D bioprinting is a promising strategy for fabrications of a wide range of organ-on-chip models, and this technology may provide the basis for organ-on-chip development and manufacturing.


Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project
Seiichi Ishida, Guest Researcher, National Institute of Health Sciences, Professor, Sojo University, Japan

Microphysiological Systems (MPS) is expected to be novel humanized in vitro test methods that addresses the unmet needs for new drug development. In Japan, the AMED-MPS project is being promoted under the leadership of AMED (the Japan Agency for Medical Research and Development) and Ministry of Economy, Trade and Industry(1). In this project, along with the development of Japan-original MPS for commercialization, there have been discussions on the technical requirements that need to be solved for MPS to be implemented in industry. Stakeholders from academia developers, suppliers of MPS, users of pharmaceutical industry, and the regulatory section are participating in these discussions actively. In this presentation, firstly the development status of Japan-original MPS will be introduced. And, secondly, we would like to present and discuss the concept of "technical requirements for industrial implementation of MPS" from the viewpoint of regulatory science based on the discussions in AMED-MPS project by showing how to establish “Context of Use” from unmet needs that MPS is required to solve and how to promote standardization of MPS. (1) Seiichi Ishida: Research and Development of Microphysiological Systems in Japan Supported by the AMED-MPS Project. Front. Toxicol. doi: 10.3389/ftox.2021.657765


Mid-Afternoon Coffee and Tea Break and Networking in the Exhibit Hall


Yong HeKeynote Presentation

3D Bioprinting: From Organ Model to Tissue Repair
Yong He, Professor, Zhejiang University, China

In this talk, we reported the recent progress in 3D bioprinting of our group. 1) Standardizing the bioinks and a framework is given for the analysis of printability during projection based 3D bioprinting(PBP); 2) How to directly print cell-laden structures with effectively vascularized nutrient delivery channels? 3) How to mimic the complex extracellular matrix with near field direct writing?


Title to be Confirmed.
Ken-ichiro Kamei, Associate Professor, Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Japan


Freeform, Reconfigurable Embedded Printing of All-Aqueous 3D Architectures
Tiantian Kong, Associate Professor, Shenzhen University, China

Aqueous microstructures are challenging to create, handle and preserve since their surfaces tend to shrink into spherical shapes with minimum surface areas. The creation of freeform aqueous architectures will significantly advance the bioprinting of complex tissue-like constructs, such as arteries, urinary catheters and tracheae. We demonstrate the generation of complex, freeform, three-dimensional (3D) all-liquid architectures using formulated aqueous two-phase systems (ATPSs). These all-liquid micro-constructs are formed by printing aqueous bioinks in an immiscible aqueous environment, which functions as a biocompatible support and a pregel solution. By exploiting the hydrogen bonding interaction between polymers in ATPS, the printed aqueous-in-aqueous reconfigurable 3D architectures can be stabilized for more than 10 days by the non-covalent membrane at the interface. Different cells can be separately combined with compartmentalized bioinks and matrices to obtain tailor-designed tissue-like constructs with perfusable vascular networks. The freeform, reconfigurable embedded printing of all-liquid architectures by ATPSs offers unique opportunities and powerful tools since limitless formulations can be designed from among a breadth of natural and synthetic hydrophilic polymers to mimic tissues. This printing approach may be useful to engineer biomimetic, dynamic tissue-like constructs with spatially defined, vascularized networks.


3D Modeling of Vascularized Barrier Tissues and Diseases For Preclinical Studies
Min Jae Song , Staff Scientist, National Center for Advancing Translational Sciences (NCATS), United States of America

In vitro three dimensional (3D) cellular models enable the study of multicellular interactions within functional tissue microenvironments. The enhanced physiological relevance of these complex 3D cellular models has opened the possibility of developing human-pathologically relevant disease assays for preclinical drug discovery and development studies. However, the increased cellular and structural complexity of these 3D cellular assays pose a significant technical challenge for their morphological and physiological validation, and use for pharmacological testing. Using 3D bioprinting techniques, we have established a robust and versatile method to engineer human vascularized tissues in a multiwell format. The bioprinting-based approach, used to biofabricate vascularized tissues, included a biodegradable polymer scaffold that enabled the addition of epithelia, in a transwell format. Several human barrier tissue models with vascularization were produced, including skin, peritoneal, and ocular tissues. Once 3D models of “healthy” tissues were biofabricated and validated, disease tissue models were developed by introducing disease-relevant chemical inducers or diseased cells, like cancer cells, into the “healthy” tissues. Treatments of the disease models with FDA approved drugs or drugs in clinical trials were able to correct the disease phenotypes. The structural, functional, and pharmacological validation of these tissues is critical to enable the use of these 3D models to accelerate the drug development process by providing pre-clinical data that it is more predictive of clinical outcomes.


Wai Yee YeongKeynote Presentation

3D-Bioprinting of Soft Tissues: Functions and Processes
Wai Yee Yeong, Programme Director and Associate Professor, Nanyang Technological University, Singapore

The bioprinting landscape is expanding and growing with exciting new advances. Different bioprinting methods have been proposed to achieve functional and biological applications from the assembly of bioactive elements. In this talk, we will focus on 3D bioprinting of soft tissues with the focus on the key functional aspects of using 3D bioprinting. Beyond just creating the shapes, 3D bioprinting process is an innovative tool for aligning cells and recreating biomimetic design of soft tissues.

Add to Calendar ▼2022-10-06 00:00:002022-10-07 00:00:00Europe/London3D-Bioprinting, Biofabrication, Organoids and Organs-on-Chips Asia 20223D-Bioprinting, Biofabrication, Organoids and Organs-on-Chips Asia 2022 in Tokyo, JapanTokyo,